<DOC>
	<DOCNO>NCT02169882</DOCNO>
	<brief_summary>Tuberculous meningitis ( TBM ) severe form tuberculosis infection high mortality . Current treatment regimen base clinical trial . Rifampicin key drug TBM , penetration brain limit , suggest high dose may effective . There several highly relevant , outstanding question related appropriate dose rifampicin TBM , multicenter phase 3 trial perform . These : 1 . Previous phase 2a randomized clinical trial ( do setting propose study ) suggest high dos intravenous rifampicin ( 600mg , circa 13 mg/mg ) TBM safe associate survival benefit adult . Given i.v . rifampicin readily available , need confirm use equivalent high oral dose rifampicin . 2 . Recent pharmacokinetic analysis continuation trial compare 600 mg i.v . rifampicin 750 mg 900 mg oral rifampicin suggest even high dose may need ; examine 3 . Based previous data , need explore long duration high-dose rifampicin subsequent phase 3 randomized clinical trial ; treatment response investigator previous trial suggest optimal duration may &gt; 14 day . 4 . There need explore relevant treatment endpoint besides mortality include neurological , neuroradiological inflammatory response .</brief_summary>
	<brief_title>High-dose Rifampicin Treatment Tuberculous Meningitis : Dose-finding Study</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Tuberculosis , Meningeal</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . Male Female , age 15 year . 2 . Clinical suspicion TBM CSF/blood glucose ratio &lt; 0.5 . 3 . None less 3 day antituberculosis chemotherapy take current infection . 4 . Patient representative ( patient incapacitate ) willing able give inform consent participation study . 5 . Willingness allow storage specimen . Patients may enter study follow apply : 1 . Liver dysfunction ( ALT &gt; 5 time upper limit ) ; kidney dysfunction ( eGFR &lt; 50 ml/min ) 2 . Pregnancy breastfeeding ( negative urine pregnancy test female childbearing age ) . 3 . Confirmed cryptococcus meningitis ( LFA ) , confirm bacterial meningitis ( microscopy ) . 4 . Rapid clinical deterioration time presentation ( e.g . sign sepsis , decrease consciousness sign cerebral oedema , herniation )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tuberculous meningitis</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Dose finding study</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>